HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide.

Abstract
Treatment with daily oral cyclophosphamide (CY) has improved survival in Wegener's granulomatosis (WG), but is associated with severe and potentially lethal adverse effects. Less toxic treatment regimens, such as pulse CY, have been used, but the effect has been questioned. We have treated 11 patients with WG with pulse CY (15 mg/kg initially every second week, gradually increasing the pulse interval). After 4.5 yr follow-up and a total of 501 pulses of CY, one patient died and eight patients (73%) were in complete remission. Remission was induced in 91% of the patients after a median period of 3.5 months and relapses were seen in 60%. With the same treatment protocol, a new complete remission was induced in 75% of those relapsing. Except for one patient who died, no patient developed end-stage renal failure. Haemorrhagic cystitis was not observed and no malignancies recorded. Severe infections were seen in 36%, but none caused by Pneumocystis carinii. Nausea was the most frequent side-effect, seen in 64% of the patients. We conclude that treatment with pulse CY every second week is safe and effective in inducing remission and treating relapses in WG. The relapse rate seems to be higher than with low-dose oral CY, but the cumulative dose of CY is less.
AuthorsW Koldingsnes, J T Gran, R Omdal, G Husby
JournalBritish journal of rheumatology (Br J Rheumatol) Vol. 37 Issue 6 Pg. 659-64 (Jun 1998) ISSN: 0263-7103 [Print] England
PMID9667621 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antirheumatic Agents
  • Cyclophosphamide
Topics
  • Adult
  • Antirheumatic Agents (administration & dosage, adverse effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Granulomatosis with Polyangiitis (drug therapy, mortality)
  • Humans
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Recurrence
  • Remission Induction
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: